Our onco-metabolism approach brings
an enhanced perspective to cancer.
- Company
- Science
- Programs
- Clinical Trials
- Media & Investors
- Financial Information
- Corporate Governance
- Shareholder Services
-
Calithera Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights
-
Calithera Biosciences to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
-
Calithera Biosciences Presents New Preclinical Data for CB-708 at AACR Annual Meeting 2019
-
Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
-
Calithera Biosciences Reports Fourth Quarter 2018 Financial Results and Recent Highlights
Development Pipeline
Calithera is committed to discovering and developing first-in-class small molecule drugs to fight tumor metabolism and tumor immunology targets differently – and to make a difference for patients.
Recent News
- Shareholder Services
- Corporate Governance
- Financial Information
- Media & Investors
- Clinical Trials
- Programs
- Science
